231 related articles for article (PubMed ID: 16113794)
1. Glycoprotein IIb/IIIa inhibition reduces prothrombotic events under conditions of deep hypothermic circulatory arrest.
Straub A; Azevedo R; Beierlein W; Wendel HP; Dietz K; Ziemer G
Thromb Haemost; 2005 Jul; 94(1):115-22. PubMed ID: 16113794
[TBL] [Abstract][Full Text] [Related]
2. Tirofiban (Aggrastat) protects platelets and decreases platelet-granulocyte binding in an extracorporeal circulation model.
Straub A; Azevedo R; Beierlein W; Wendel HP; Dietz K; Ziemer G
Thorac Cardiovasc Surg; 2006 Apr; 54(3):162-7. PubMed ID: 16639676
[TBL] [Abstract][Full Text] [Related]
3. Hypothermia-induced platelet aggregation: no effect of aprotinin (trasylol) but inhibition by eptifibatide (integrilin).
Straub A; Azevedo R; Beierlein W; Wendel HP; Scheule AM; Ziemer G
Thorac Cardiovasc Surg; 2005 Apr; 53(2):80-4. PubMed ID: 15786005
[TBL] [Abstract][Full Text] [Related]
4. Platelet anaesthesia during extracorporeal circulation: differential effects of GP IIb/IIIa blockers on platelet activation marker P-selectin expression at hypothermia.
Straub A; Schiebold D; Wendel HP; Azevedo R; Dietz K; Ziemer G
Thromb Res; 2008; 122(3):383-9. PubMed ID: 18304613
[TBL] [Abstract][Full Text] [Related]
5. The GP IIb/IIIa inhibitor abciximab (ReoPro) decreases activation and interaction of platelets and leukocytes during in vitro cardiopulmonary bypass simulation.
Straub A; Wendel HP; Azevedo R; Ziemer G
Eur J Cardiothorac Surg; 2005 Apr; 27(4):617-21. PubMed ID: 15784360
[TBL] [Abstract][Full Text] [Related]
6. Dissociation of glycoprotein IIb/IIIa antagonists from platelets does not result in fibrinogen binding or platelet aggregation.
Frelinger AL; Furman MI; Krueger LA; Barnard MR; Michelson AD
Circulation; 2001 Sep; 104(12):1374-9. PubMed ID: 11560852
[TBL] [Abstract][Full Text] [Related]
7. Effect of glycoprotein IIb/IIIa inhibitors on CD62p expression, platelet aggregates, and microparticles in vitro.
Matzdorff AC; Kühnel G; Kemkes-Matthes B; Pralle H; Voss R; Fareed J
J Lab Clin Med; 2000 Mar; 135(3):247-55. PubMed ID: 10711863
[TBL] [Abstract][Full Text] [Related]
8. Augmentation of inhibitory effects of glycoprotein IIb-IIIa antagonists in patients with diabetes.
Keating FK; Whitaker DA; Sobel BE; Schneider DJ
Thromb Res; 2004; 113(1):27-34. PubMed ID: 15081562
[TBL] [Abstract][Full Text] [Related]
9. Ability of anti-glycoprotein IIb/IIIa agents to dissolve platelet thrombi formed on a collagen surface under blood flow conditions.
Goto S; Tamura N; Ishida H
J Am Coll Cardiol; 2004 Jul; 44(2):316-23. PubMed ID: 15261925
[TBL] [Abstract][Full Text] [Related]
10. Selective inhibition of the platelet phosphoinositide 3-kinase p110beta as promising new strategy for platelet protection during extracorporeal circulation.
Straub A; Wendel HP; Dietz K; Schiebold D; Peter K; Schoenwaelder SM; Ziemer G
Thromb Haemost; 2008 Mar; 99(3):609-15. PubMed ID: 18327411
[TBL] [Abstract][Full Text] [Related]
11. Pharmacologic cerebral capillary blood flow improvement after deep hypothermic circulatory arrest: an intravital fluorescence microscopy study in pigs.
Ben Mime L; Arnhold S; Fischer JH; Addicks K; Rainer de Vivie E; Bennink G; Suedkamp M
J Thorac Cardiovasc Surg; 2005 Sep; 130(3):670-6. PubMed ID: 16153911
[TBL] [Abstract][Full Text] [Related]
12. Glycoprotein IIb/IIIa inhibitors increase COAT-platelet production in vitro.
Hamilton SF; Miller MW; Thompson CA; Dale GL
J Lab Clin Med; 2004 May; 143(5):320-6. PubMed ID: 15122176
[TBL] [Abstract][Full Text] [Related]
13. Variable responses to inhibition of fibrinogen binding induced by tirofiban and eptifibatide in blood from healthy subjects.
Holmes MB; Sobel BE; Schneider DJ
Am J Cardiol; 1999 Jul; 84(2):203-7. PubMed ID: 10426341
[TBL] [Abstract][Full Text] [Related]
14. Paradoxical inhibition of fibrinogen binding and potentiation of alpha-granule release by specific types of inhibitors of glycoprotein IIb-IIIa.
Schneider DJ; Taatjes DJ; Sobel BE
Cardiovasc Res; 2000 Jan; 45(2):437-46. PubMed ID: 10728364
[TBL] [Abstract][Full Text] [Related]
15. Incomplete inhibition of platelet aggregation and glycoprotein IIb-IIIa receptor blockade by abciximab: importance of internal pool of glycoprotein IIb-IIIa receptors.
Gawaz M; Ruf A; Pogatsa-Murray G; Dickfeld T; Rüdiger S; Taubitz W; Fischer J; Müller I; Meier D; Patscheke H; Schömig A
Thromb Haemost; 2000 Jun; 83(6):915-22. PubMed ID: 10896249
[TBL] [Abstract][Full Text] [Related]
16. Differential inhibitory effects of platelet glycoprotein IIb/IIIa antagonists on aggregation induced by procoagulant agonists.
Ilveskero S; Lassila R
Thromb Res; 2006; 117(3):291-7. PubMed ID: 15878612
[TBL] [Abstract][Full Text] [Related]
17. Comparative efficacy of fibrinogen and platelet supplementation on the in vitro reversibility of competitive glycoprotein IIb/IIIa receptor-directed platelet inhibition.
Li YF; Spencer FA; Becker RC
Am Heart J; 2002 Apr; 143(4):725-32. PubMed ID: 11923812
[TBL] [Abstract][Full Text] [Related]
18. Release of soluble CD40L from platelets is regulated by glycoprotein IIb/IIIa and actin polymerization.
Furman MI; Krueger LA; Linden MD; Barnard MR; Frelinger AL; Michelson AD
J Am Coll Cardiol; 2004 Jun; 43(12):2319-25. PubMed ID: 15193700
[TBL] [Abstract][Full Text] [Related]
19. Variation in the ability of glycoprotein IIb-IIIa antagonists to exert and maintain their inhibitory effects on the binding of fibrinogen.
Schneider DJ; Baumann PQ; Whitaker DA; Sobel BE
J Cardiovasc Pharmacol; 2005 Jul; 46(1):41-5. PubMed ID: 15965353
[TBL] [Abstract][Full Text] [Related]
20. The GPIIb/IIIa antagonist eptifibatide markedly potentiates platelet-leukocyte interaction and tissue factor expression following platelet activation in whole blood in vitro.
Scholz T; Zhao L; Temmler U; Bath P; Heptinstall S; Lösche W
Platelets; 2002 Nov; 13(7):401-6. PubMed ID: 12487787
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
